Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression

International Journal of Cancer

Volumn 108, Issue 1, 2004, Pages 31-40

  Tanaka, Keiichiro ^a,b   Hiraiwa, Noriko ^b   Hashimoto, Hisashi ^a,b   Yamazaki, Yoji ^a   Kusakabe, Moriaki ^a,c  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RIKEN   (Japan)

^c Aloka Co Ltd   (Japan)

Author keywords

Angiogenesis; Cell cell interactions; Extracellular matrix molecules; Tenascin C; Vascular endothelial growth factor

Indexed keywords

TENASCIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL INTERACTION; CELL TRANSPLANTATION; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; EMBRYO; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENOTYPE; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MELANOMA; MELANOMA CELL; MESENCHYME; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; WILD TYPE;

ANIMALS; ANIMALS, CONGENIC; COCULTURE TECHNIQUES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MESODERM; MICE; MICE, KNOCKOUT; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; TENASCIN; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0345256408     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11509     Document Type: Article

References (35)

1. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura, T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986;47:131-9.
2. Spring J, Beck K, Chiquet-Ehrismann R. Two contrary functions of tenascin: dissection of the active sites by recombinant tenascin fragments. Cell 1989;59:325-34.
3. Chiquet-Ehrismann R. What distinguishes tenascin from fibronectin? FASEB J 1990;4:2598-604.
4. Chiquet-Ehrismann R, Kalla P, Pearson CA, Beck K, Chiquet M. Tenascin interferes with fibronectin action. Cell 1988;53:383-90.
5. Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev 1992;6:1821-31.
6. Natali PG, Nicotra MR, Bigotti A, Botti C, Castellani P, Risso AM, Zardi L. Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. Int J Cancer 1991;47:811-6.
7. Sakakura T, Kusano I. Tenascin in tissue perturbation repair. Acta Pathol Jpn 1991;41:247-58.
8. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000;218:235-59
9. Aufderheide E, Chiquet-Ehrismann R, Ekblom P. Epithelial-mesenchymal interactions in the developing kidney lead to expression of tenascin in the mesenchyme. J Cell Biol 1987;105:599-608.
10. Inaguma Y, Kusakabe M, Mackie EJ, Pearson CA, Chiquet-Ehrismann R, Sakakura T. Epithelial induction of stromal tenascin in the mouse mammary gland: from embryogenesis to carcinogenesis. Dev Biol 1988;128:245-55.
11. Hiraiwa N, Kida H, Sakakura T, Kusakabe M. Induction of tenascin in cancer cells by interactions with embryonic mesenchyme mediated by a diffusible factor. J Cell Sci 1993;104:289-96.
12. Mackie EJ, Halfter W, Liverani D. Induction of tenascin in healing wounds. J Cell Biol 1988;107:2757-67.
13. Chiquet M, Fambrough DM. Chick mytotendinous antigen: I, a monoclonal antibody as a marker for tendon and muscle morphogenesis. J Cell Biol 1984;98:1926-36.
14. Chiquet M, Fambrough DM. Chick mytotendinous antigen: II, a novel extracellular glycoprotein complex consisting of large disulfide-linked subunits. J Cell Biol 1984;98:1937-46.
15. Ishihara A, Yoshida T, Tamaki H, Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res 1995;1:1035-41.
16. Kusakabe M, Sakakura T. Extracellular matrix in tissue remodeling: Tenascin-C as a modulator in cell-matrix interactions. In: Ninomiya Y, et al., eds. Extracellular matrix-cell interaction: molecules to diseases. Tokyo: Japan Science Society Press, 1998. 87-107.
17. Mackie EJ, Tucker RP. The tenascin-C knockout revisited. J Cell Sci 1999;112:3847-53.
18. Nakao N, Hiraiwa N, Yoshiki A, Ike F, Kusakabe M. Tenascin-C promotes healing of habu-snake venom-induced glomerulonephritis. Am J Pathol 1998;152:1237-45.
19. Koyama Y, Kusubata M, Yoshiki A, Hiraiwa N, Ohashi T, Irie S, Kusakabe M. Effect of tenascin-C deficiency on chemically induced dermatitis in the mouse. J Invest Dermatol 1998;111:930-5.
20. Fukamauchi F, Mataga N, Wang Y-J, Sato S, Yoshiki A. Kusakabe M. Abnormal behavior and neurotransmissions of tenascin gene knockout mouse. Biochem Biophys Res Commun 1996;221:151-6.
21. Fukamauchi F, Aihara O, Kusakabe M. Internalization and down-regulation of muscarinic acetylcholine receptors in cerebellar granule cells of tenascin-gene deficient mice. Neurochem Int 2000;36:153-8.
22. Steindler DA, Settles D, Erickson HP, Laywell ED, Yoshiki A, Faissner A, Kusakabe M. Tenascin knockout mice: barrels, boundary molecules, and glial scars. J Neurosci 1995;15:1971-83.
23. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
24. Folkman J. Tumor angiogenesis. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Pollock RE, Weichselbaum RR, eds. Cancer medicine, 5th ed. Ontario, Canada: BC Decker, 2000. 132-52.
25. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
26. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
27. Lee KY, Peters MC, Anderson KW, Mooney DJ. Controlled growth factor release from synthetic extracellular matrices. Nature 2000;408: 998-1000.
28. Detmar M. Tumor angiogenesis. J Invest Dermatol Symp Proc 2000; 5:20-3.
29. Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 2001;280:C1367-74.
30. Hashimoto H, Ishikawa H, Kusakabe M. Simultaneous observation of capillary nets and tenascin in intestinal villi. Anat Rec 1998;250:488-92.
31. Hashimoto H, Ishikawa H, Kusakabe M. Preparation of whole mounts and thick sections for confocal microscopy. Methods Enzymol 1999; 307:84-107.
32. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64.
33. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-4.
34. Kawakatsu H, Shiurba R, Obara M, Hiraiwa H, Kusakabe M, Sakakura T. Human carcinoma cells synthesize and secrete Tenascin in vitro. Jpn J Cancer Res 1992;83:1073-80.
35. Kusakabe M, Takaku K, Matsuzaki T, Inoue J, Yoshiki A, Hiraiwa N. Effect of the tenascin inducing factor on tumor growth and lung metastasis, In: Ioannidou-Mouzaka L, Agnatis NJ, Lopez DM, eds. 22nd Congress of the International Association for Breast Cancer Research. Bologna: Monduzzi Editore, 1999. 197-201.